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Abstract 
Background: Optimal HIV treatment monitoring remains a big challenge in resource limited settings. Guidelines rec-
ommend the use of clinical and immunological criteria in resource limited settings due to unavailability of viral load 
monitoring; however their utility is questionable. This study aimed at assessing the accuracy of immunological criteria 
in detecting treatment failure among HIV infected Tanzanian adults receiving first line ART.
Methods: A clinic based cross sectional study was conducted between February and July 2011 at Bugando Medical 
centre (BMC) HIV care and treatment clinic (CTC) involving HIV infected patients aged 18 years and above, receiving 
first line ART; followed up for at least 1 year. Viral load was tested for every enrolled patient. Standard WHO criteria 
were used to define immunological failure. Virological failure was defined as one viral load measurement of >5000 
copies/ml and was used as a gold standard. A 2 × 2 table was used to assess the accuracy of immunological criteria in 
detecting treatment failure.
Results: A total of 274 HIV-infected adults were enrolled into the study. Out of these, 65.7% were females, the median 
age was 39 years (IQR 33–45), the median BMI 21.9 kg/m2 (IQR 19.7–24.0). Out of the 274 study participants 156 
(56.9%) had immunological failure. Only 60 of the study participants (21.9%) had viral load >5000. Only 42 patients 
(70%) were found to have both immunological failure and virological failure. The sensitivity of immunological criteria 
in detecting treatment failure was 70%, specificity 46.7%, positive predictive and negative predictive values of 26.9 
and 84.7% respectively.
Conclusion: WHO immunological criteria have low sensitivity and positive predictive value for detecting treatment 
failure. Relying on CD4 counts for treatment monitoring would therefore lead to misclassifications of treatment failure 
that could result into unnecessary or delayed switch to second line ART. Access to viral load monitoring is important 
to avoid these misclassifications.
Keywords: HIV/AIDS, Antiretroviral therapy, Treatment failure, Immunological monitoring
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
BMC Research Notes
*Correspondence:  boniempondo@gmail.com 
4 Department of Medicine, College of Health Sciences, The University 
of Dodoma, P.O Box 395, Dodoma, Tanzania
Full list of author information is available at the end of the article
Page 2 of 5Gunda et al. BMC Res Notes  (2017) 10:45 
Background
HIV remains a public health concern in sub-Saharan 
Africa despite the epidemic being on its 3rd decade. Esti-
mates show that up to 70% of HIV cases are still found 
in sub-Saharan Africa [1]. Efforts from the World Health 
Organization (WHO) and the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) have ensured rapid 
scaling up of antiretroviral therapy in resource limited 
settings (RLS) [2]. In 2011, it was estimated that 6.6 mil-
lion people were receiving ART. Despite the reduction in 
mortality following the scaling up of antiretroviral ther-
apy (ART) use, optimal monitoring for treatment failure 
remains a big challenge in RLS.
Guidelines for the use of ART in resource limited set-
tings (RLS) where viral load monitoring is not routinely 
available recommend the use of CD4 count and clini-
cal monitoring to diagnose treatment failure [3]. WHO 
guidelines for a public health approach to ART define 
immunological failure as: the fall off CD4 count to below 
baseline in the absence of concurrent infections, a fall of 
more than 50% from the peak value or persistent CD4 
below 100 cells/mm3 while on treatment [3]. Viral load 
monitoring which is the gold standard in detecting treat-
ment failure is not readily available in RLS because of the 
cost and technical requirements of the assay.
Several studies have found low sensitivity and positive 
predictive value of the WHO immunological criteria on 
predicting treatment failure [4–7]. This leads to mis-
classifications and unnecessary switching off to second 
line ART in patients with adequate virological suppres-
sion. However, there are no studies assessing the sensi-
tivity of the immunological criteria from Tanzania. This 
study therefore aimed at assessing the accuracy of WHO 
immunological criteria in detecting ART treatment fail-
ure in HIV-infected adults taking first line ART.
Methods
Study design
This was a clinic based cross sectional study done at 
Bugando Medical Centre (BMC) HIV care and treatment 
clinic (CTC) between February and July 2011.
Study setting
The study was conducted at Bugando care and treatment 
centre (CTC) in Mwanza, Tanzania. Bugando is a tertiary 
and teaching hospital for the Lake Zone of Tanzania. The 
hospital serves around 13 million people from 6 regions 
of the Lake Zone, which are Mwanza, Kagera, Shinyanga, 
Tabora, Mara and Kigoma. The hospital runs both inpa-
tient and outpatient treatment activities, with an approxi-
mate bed capacity of 900. CTC activities is one of the 
core part of outpatient activities, which started in 2004, 
and currently it serves more than ten thousand patients, 
of whom about 5000 are on ARTs. More than two-thirds 
of these patients are on first line regimens and the rest 
are on the second line regime.
Study participants
The study involved 274 adult HIV-infected patients aged 
18  years and above enrolled to HIV care and initiated 
on first line ART, with a minimum follow up of 1-year. 
Patients who were critically ill, with concurrent infec-
tions, and those on second line were excluded from the 
study.
Sample size and sampling
Sample size was estimated using Kish and Leslie for-
mula. A minimum sample size was 220 patients obtained 
by assuming that 50% of the patients on first line ART 
will have virological failure. Patients fulfilling the inclu-
sion criteria were serially enrolled until sample size was 
reached.
Data collection and laboratory analysis
The adult HIV patients on first line ART with a mini-
mum follow up of 1  year (12-months) were identi-
fied from daily CTC listing at Bugando on routine 
basis and they were invited to participate in this study. 
These patients are usually followed up monthly or 
after every 2-month depending on their clinical status. 
CD4 measurements are usually routinely performed 
after every 6-month. After giving consent a structured 
questionnaire was used to collect information regard-
ing, demographic data, date of diagnosis of HIV, date 
of ART initiation and regime, compliance level which 
was assessed using patient response method, BMI, TB 
status, co morbidities, co medications, CD4, VL, ART 
serum levels, and other routine laboratory. For each 
patient enrolled into the study, 1.5 ml of blood was col-
lected in an EDTA bottle for viral load. This sample 
was also centrifuged in the ICU side lab, at 3000  rpm 
to obtain plasma which was again transferred into cry-
ovials and sent to BMC main lab for viral load using 
FACS—calibur analyzers according to manufacturer’s 
guidelines.
Statistical analysis
The data was entered, verified and a cleaned, using 
Microsoft excel spread and the data analysis was done 
using STATA version 14 (College Station, Texas). Con-
tinuous variables were summarized by medians and 
interquartile ranges (IQRs) and categorical variables were 
summarized by frequency and percentage. A 2 × 2 table 
was used to assess the accuracy of the immunological cri-
teria for detecting treatment failure using viral load as the 
gold standard.
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Definitions of treatment failure
Definitions for immunological failure were derived from 
the WHO guideline for this analysis [3]. A participant 
was therefore considered to have immunological failure 
if one of the following criteria was met: (1) fall of CD4 
count to pre-therapy baseline or below, (2) ≥50% fall of 
absolute CD4 count from the on-treatment peak value or 
(3) persistent CD4 levels below 100 cells/mm3; all in the 
absence of concurrent infections. Virological failure was 




This study was approved by Bugando Medical centre 
(BMC)/Catholic University of Health and Allied Sciences 
(CUHAS) joint research and ethical committee. Further 
approval was sought from the department of Internal 
medicine, Bugando Medical centre.
Consent to participate
Informed consent to participate in the study was 
obtained from all study participants. The study enrolled 
only patients who provided written consent. All patients 
with immunological failure were switched into second 
line of ARV following failure of improvement of their 
CD4 two weeks of intensified adherence and in some 
with virological proof of ARV treatment failure as per 
existing treatment guidelines. Patients who declined con-
sent were not denied of their services.
Results
A total of 274 HIV-infected adults were enrolled into the 
study. Out of the study participants, 65.7% were females, 
the median age was 39  years (IQR 33–45), the median 
BMI 21.9  kg/m2 (IQR 19.7–24.0) (Table  1). Majority of 
the study participants (47.8%) presented with WHO clin-
ical stage 3, the median baseline CD4 count being 139.5 
cells/mm3 (IQR 60–210). Most of the study participants 
(97.4%) had adherence level of >95%.
Based on the WHO criteria for immunological failure, 
out of the 274 study participants 156 (56.9%) met the 
criteria. Only 60 of the study participants (21.9%) had 
viral load >5000. Only 42 participants out of the 60 with 
confirmed virological failure (70%) were found to have 
both immunological failure and virological failure. The 
sensitivity of immunological criteria in detecting treat-
ment failure was therefore 70% with specificity and posi-
tive predictive values of 46.7 and 26.9% respectively. The 
negative predictive value was found to be 84.7% (Table 2). 
30% of the study participants who fulfilled the criteria 
for virological failure did not fulfill any of the criteria 
for immunological failure. Out of the 156 patients who 
fulfilled criteria for immunological failure, 73.1% were 
virologically suppressed.
Discussion
In this study, the performance of WHO immunological 
criteria in detecting treatment failure was poor. Despite 
a relatively high NPV (84.7%), the PPV was low (26.9%). 
Using the WHO immunological criteria would miss up to 
30% of the patients who were truly having treatment fail-
ure while it would misclassify as treatment failure 73.1% 
virologically suppressed patients. In this cohort, 21.9% of 
the participants had virological failure.
These findings are consistent with studies elsewhere in 
resource limited settings. A study analyzing data from 
10 programmes in Africa and south America found that 
the PPV ranged from 10 to 30% with a relatively higher 
Table 1 Baseline characteristics of  HIV-infected adults 
attending BMC-CTC (n = 274)
Variable Number (%) or median (IQR)
Age (years) 39 (33–45)
Gender
 Female 178 (65.7)
 Males 93 (34.3)
Baseline CD4 (cells/mm3) 139.5 [IQR 60–210]
WHO stage
  Stage 1 11 (4.0)
  Stage 2 66 (24.1)
  Stage 3 131 (47.8)
  Stage 4 66 (24.1)
BMI (kg/m2) 21.9 (19.7–24.0)
ARV regimes
  Stavudine based 34 (12.4)
  Zidovudine based 129 (47.1)
  Tenofovir based 111 (40.5)
Adherence level (%)
 >95 267 (97.4)
 <95 7 (2.6)
Table 2 Test characteristics of  WHO immunological crite-
ria to  detect treatment failure among HIV infected adults 
(n = 274)
Sensitivity 70%, specificity 46.7%, positive predictive value 26.9%, negative 
predictive value 84.7%
Immunological failure Virological failure
Yes No Total
Yes 42 114 156
No 18 100 118
Total 60 214 274
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NPV [4]. Another study done in Kenya found that immu-
nological criteria had a PPV of 24.5% with a 95.2% NPV. 
Another study done in Nigeria found a PPV of 39.2% 
and a NPV of 86.7% more or less similar to our study [8]. 
Another study done in India found that WHO immuno-
logical criteria had a PPV of 34.2% [9].
The low PPV found in this study means that only a few 
of the patients that were identified as having treatment 
failure by the immunological criteria were actually having 
treatment failure. The false positive rate of immunologi-
cal criteria for this study was 73.1%. This is comparable 
to a study done in Nigeria which found the false positive 
rate to be around 60.8%. The low specificities and PPV of 
immunological criteria found in our study, that is similar 
to many other studies in Africa and other RLS mean that 
patients with adequate viral suppression are at risk of 
being classified as having treatment failure and switched 
to second line. Monitoring treatment failure using immu-
nological and/or clinical criteria is associated with the 
emergence of nucleoside reverse transcriptase inhibitor 
and non-nucleoside reverse transcriptase inhibitor resist-
ance [10]. Based on immunological criteria in this study, 
30% of the patients would have been classified as not fail-
ing, and therefore not switched to second line. Failure to 
switch a failing regimen has been shown to result into 
accumulation of mutations that will limit future treat-
ment options [9, 11].
The sensitivity in this study was relatively higher com-
pared to other studies. This could be explained by the cut 
off used in this study (>5000 copies/ml) which has been 
suggested by WHO to increase sensitivity in resource 
limited settings [3]. Another study done in Nigeria using 
different definitions of virological failure found a sensitiv-
ity of 66.2% when the cut off similar to the one we used 
for our study was chosen [8]. Another study compar-
ing the different thresholds for virological failure found 
that the high threshold is associated with high sensitivity 
when compared to low threshold [4].
A systematic review that assessed the 2010 WHO 
immunological criteria found that these criteria have 
low sensitivity and positive predictive value in identify-
ing individuals with virological failure [12]. The sensitiv-
ity and specificity would be expected to be even lower if 
the ART is initiated at relatively higher CD4 cell count. 
WHO in 2013 guideline concludes that there is currently 
no proposed alternative definition of treatment failure 
and no validated alternative definition of immunologi-
cal failure [3]. Studies done in children also found low 
sensitivity and positive predictive value when immuno-
logical criteria were used [13, 14]. Based on these facts, 
WHO recommends routine viral load monitoring (every 
6–12 months) to enhance earlier and accurate detection 
of treatment failure [3]. In settings with limited settings 
to routine viral load monitoring, WHO recommends 
targeted viral load strategy to confirm treatment failure 
diagnosed based on clinical and immunological crite-
ria. Despite the fact that targeted viral load strategy may 
delay switching to second line and thereby increase the 
risk of disease progression, it helps to avoid unnecessary 
switching to second line that could have happened when 
clinical and immunological criteria were used alone [15].
Our study had several limitations. We could not con-
sider clinical outcomes linked with the treatment failure. 
Such information is not routinely collected during clinic 
visits. It was not possible therefore to assess the link 
between the clinical criteria; we had to focus therefore 
on laboratory criteria. The study was a cross-sectional 
study. Longitudinal study design would have been a bet-
ter design for such a study question. These findings were 
from a single clinic; the results may not be generalizable 
to the general population therefore. Our study however 
is the first study in Tanzania comparing immunological 
criteria that is the one most used and the gold standard 
virological criteria in diagnosing treatment failure. It also 
adds more emphasis on the disadvantages of switching 
clients to second line based on clinical and immunologi-
cal criteria that have low sensitivity and positive predic-
tive value; this outlines the need for confirmatory viral 
load test.
Conclusion
CD4 criteria for the detection of treatment failure 
have poor performance for detecting virological failure 
based on WHO-definition. The low specificity and posi-
tive predictive values indicate that using CD4 criteria 
increases the risk of misclassifications; individuals with 
adequate virological suppression may be misdiagnosed 
with treatment failure leading to unnecessary switches 
while those with virological failure may be missed lead-
ing to delay in switching. This further highlights the 
need to confirm virological failure before switching to 
second line. Targeted viral load strategy should be used 
in resource limited settings to confirm treatment fail-
ure in cases suspected by clinical and immunological 
criteria.
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